专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10078085B2 Screening and engineering method of super-stable immunoglobulin variable domains and their uses 有权
公开(公告)号：US10078085B2
公开(公告)日：2018-09-18
申请号：US14422912
申请日：2012-08-22
申请人： Hyung-Kwon Lim , Sung Geun Kim , Young Seoub Park , Hyo Jung Nam , Dong-Sik Kim , Jae Chan Park , Yeup Yoon
发明人： Hyung-Kwon Lim , Sung Geun Kim , Young Seoub Park , Hyo Jung Nam , Dong-Sik Kim , Jae Chan Park , Yeup Yoon
IPC分类号： C40B40/10 , G01N33/68 , C07K16/00 , C07K16/18 , C07K16/32
CPC分类号： G01N33/6857 , C07K16/00 , C07K16/18 , C07K16/32 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/94 , C07K2319/00 , C07K2319/10 , C40B40/10 , G01N2500/00
摘要： There are provided a method named Tat-associated protein engineering (TAPE), of screening a target protein having higher solubility and excellent thermostability, in particular, an immunoglobulin variable domain (VH or VL) derived from human germ cells, by preparing a gene construct where the target protein and an antibiotic-resistant protein are linked to a Tat signal sequence, and then expressing this within E. coli, and human or engineered VH and VL domain antibodies and human or engineered VH and VL domain antibody scaffolds having solubility and excellent thermostability, which are screened by the TAPE method. There are also provided a library including random CDR sequences in the human or engineered VH or VL domain antibody scaffold screened by the TAPE method, and a preparing method thereof. There are also provided a VH or VL domain antibody having binding ability to the target protein screened by using the library, and a pharmaceutical composition including the domain antibody.

2. 发明申请

US20100256073A1 THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 审中-公开
标题翻译：包含LOCOCALIN 2抗癌剂的治疗药物，以及早期诊断方法和使用LIPOCALIN 2抑制癌症METASTASIS
公开(公告)号：US20100256073A1
公开(公告)日：2010-10-07
申请号：US12779911
申请日：2010-05-13
申请人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-hong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
发明人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-hong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
IPC分类号： A61K38/16 , A61P35/00 , A61P35/04
CPC分类号： A61K38/1709 , A61K48/00 , C12N15/86 , C12N2740/15043
摘要： The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
摘要翻译：本发明涉及用于抑制癌症转移的药物组合物，更准确地说，涉及一种抗癌转移的新型药物组合物，其包含脂质运载蛋白2蛋白，编码该蛋白质的基因，含有表达载体转染的基因或表达载体的表达载体有效成分，使用该组合物抑制癌症转移的方法，用于预测癌症转移的诊断试剂盒，使用试剂盒选择转移风险组的方法，用于抑制癌症生长的新型药物组合物以及使用其抑制癌症生长的方法。本发明的药物组合物特异性地抑制癌症转移，从而可以显着地改善癌症治疗的效果。并且，使用该试剂盒的诊断试剂盒和选择转移风险组的方法能够通过测量肿瘤组织或体液中脂笼蛋白2的水平来选择转移风险组。因此，试剂盒和方法可以有助于癌症患者的有效临床控制。此外，本发明的组合物由于其肝癌生长抑制作用，可以有效地用于治疗肝癌。

3. 发明申请

US20100196370A1 FUSION PROTEIN OF IMMUNOGLOBULIN FC AND HUMAN APOLIPOPROTEIN(A) KRINGLE FRAGMENT 审中-公开
标题翻译：免疫球蛋白FC和人APOLIPOPROTEIN的融合蛋白（A）KRINGLE FRAGMENT
公开(公告)号：US20100196370A1
公开(公告)日：2010-08-05
申请号：US12519653
申请日：2007-11-16
申请人： Hyun-Kyung Yu , Yeup Yoon , Jin-Hyung Ahn , In-Hwan Lim , Ho-Jeong Lee , Jang-Seong Kim , Doo-Hong Park
发明人： Hyun-Kyung Yu , Yeup Yoon , Jin-Hyung Ahn , In-Hwan Lim , Ho-Jeong Lee , Jang-Seong Kim , Doo-Hong Park
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/06 , A61P35/04
CPC分类号： C07K14/775 , C07K2319/31
摘要： The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.
摘要翻译：本发明涉及具有增加的血管发生抑制活性和体内稳定性的LK8-Fc融合蛋白。更具体地，涉及其中具有血管生成抑制活性的LK8蛋白与人免疫球蛋白IgG1的Fc区融合的LK8-Fc融合蛋白以及含有融合蛋白的用于治疗癌症的组合物。 LK8-Fc融合蛋白不仅具有导致抗癌和转移抑制活性的血管发生抑制活性，而且具有非常长的体内半衰期，因此可用作更有效和经济的癌症治疗剂或癌症抑制剂。

4. 发明申请

US20110008885A1 LINEAR DOUBLE-STRANDED RNA MOLECULE INTERFERING WITH DIFFERENT TARGET GENES 审中-公开
标题翻译：线性双链RNA分子与不同目标基因的干扰
公开(公告)号：US20110008885A1
公开(公告)日：2011-01-13
申请号：US12667738
申请日：2008-07-07
申请人： Meehyein Kim , Duckhyang Shin , Hyeon Lee , Soo In Kim , Yeup Yoon
发明人： Meehyein Kim , Duckhyang Shin , Hyeon Lee , Soo In Kim , Yeup Yoon
IPC分类号： C12N5/071 , C07H21/02 , C12N15/63
CPC分类号： C12N15/111 , C12N2310/111 , C12N2310/14 , C12N2310/51
摘要： A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.
摘要翻译：线性双链RNA分子，其包含两个或更多个连续或趋向连接的短干扰RNA（siRNA），每个短干扰RNA减少一个不同靶基因的表达;以及重组表达载体，其包含表达线性双链RNA的双链DNA序列，提供了双链RNA分子。线性双链RNA分子或重组表达载体可用于减少细胞中靶基因表达的方法，该方法包括将线性双链RNA分子或重组表达载体引入细胞，由此编码 siRNA靶向不同的基因并减少靶基因的表达。还证明当线性双链RNA分子内的每个siRNA单元具有18至24个核苷酸时，可以诱导有效的基因沉默活性，此外，基因沉默活性不受siRNA反向取向的影响。

5. 发明申请

US20100209491A1 METHOD FOR ENHANCING SERUM STABILITY AND LOWERING IMMUNE RESPONSE OF SIRNA DOWN-REGULATING GENE EXPRESSION OF HBV OR HCV 审中-公开
标题翻译：用于增强血清稳定性和降低SIRNA下调HBV基因表达的免疫应答方法
公开(公告)号：US20100209491A1
公开(公告)日：2010-08-19
申请号：US12678469
申请日：2008-05-08
申请人： Soo In Kim , Duckhyang Shin , Hyeon Lee , Meehyein Kim , Doo-Hong Park , Yeup Yoon
发明人： Soo In Kim , Duckhyang Shin , Hyeon Lee , Meehyein Kim , Doo-Hong Park , Yeup Yoon
IPC分类号： A61K31/713 , C07H21/02 , A61K9/127 , A61P31/20
CPC分类号： C07H21/02 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12N2320/51 , C12N2320/53 , C12N2310/3521
摘要： A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.
摘要翻译：提供了一种提高针对乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）的病毒基因表达介导RNA干扰（RNAi）的小干扰核糖核酸（siRNA）的血清稳定性和降低免疫刺激性的方法。

6. 发明申请

US20090311224A1 THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 审中-公开
标题翻译：包含LOCOCALIN 2抗癌剂的治疗药物，以及早期诊断方法和使用LIPOCALIN 2抑制癌症METASTASIS
公开(公告)号：US20090311224A1
公开(公告)日：2009-12-17
申请号：US11815088
申请日：2006-02-24
申请人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-bong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
发明人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-bong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
IPC分类号： A61K35/12 , C07H21/00 , C12N15/63 , C12N5/00 , A61K31/7052 , C07K14/00 , A61K38/16 , C07K16/00 , A61P35/00 , C12Q1/68
CPC分类号： A61K38/1709 , A61K48/00 , C12N15/86 , C12N2740/15043
摘要： The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
摘要翻译：本发明涉及用于抑制癌症转移的药物组合物，更准确地说，涉及一种抗癌转移的新型药物组合物，其包含脂质运载蛋白2蛋白，编码该蛋白质的基因，含有表达载体转染的基因或表达载体的表达载体有效成分，使用该组合物抑制癌症转移的方法，用于预测癌症转移的诊断试剂盒，使用试剂盒选择转移风险组的方法，用于抑制癌症生长的新型药物组合物以及使用其抑制癌症生长的方法。本发明的药物组合物特异性地抑制癌症转移，从而可以显着地改善癌症治疗的效果。并且，使用该试剂盒的诊断试剂盒和选择转移风险组的方法能够通过测量肿瘤组织或体液中脂笼蛋白2的水平来选择转移风险组。因此，试剂盒和方法可以有助于癌症患者的有效临床控制。此外，本发明的组合物由于其肝癌生长抑制作用，可以有效地用于治疗肝癌。

7. 发明授权

US07285277B2 Anticancer agent 失效
标题翻译：抗癌剂
公开(公告)号：US07285277B2
公开(公告)日：2007-10-23
申请号：US11162817
申请日：2005-09-23
申请人： Jang-Seong Kim , Jin-Hyung Ahn , Hyun-Kyung Yu , Ho-Jeong Lee , Doo-Hong Park , Yeup Yoon
发明人： Jang-Seong Kim , Jin-Hyung Ahn , Hyun-Kyung Yu , Ho-Jeong Lee , Doo-Hong Park , Yeup Yoon
IPC分类号： A61K39/00 , A61K38/03
CPC分类号： A61K38/1709
摘要： The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.
摘要翻译：本申请公开了一种减少肿瘤生长的方法，其包括使肿瘤与具有肿瘤生长的有效量的包含LK8或LK68蛋白或其功能等同的氨基酸变体和其药学上可接受的载体的组合物接触肿瘤。

8. 发明授权

US07259010B2 Expression vector for animal cell containing nuclear matrix attachment region of interferon beta 有权
标题翻译：含有干扰素β核基质附着区的动物细胞的表达载体
公开(公告)号：US07259010B2
公开(公告)日：2007-08-21
申请号：US10450556
申请日：2001-12-14
申请人： Jeong Do Kim , Hye-Yeon Hwang , Dong-jun Kim , Kwanghee Baek , Yeup Yoon , Jaeseung Yoon , Alex Inkeun Leesong
发明人： Jeong Do Kim , Hye-Yeon Hwang , Dong-jun Kim , Kwanghee Baek , Yeup Yoon , Jaeseung Yoon , Alex Inkeun Leesong
IPC分类号： C12N15/63
CPC分类号： C07K14/565 , C12N15/85 , C12N2830/46
摘要： The present invention relates to mammalian expression vectors including nuclear matrix attachment region of human interferon β, and more particularly to pPGM-1, pPGM-2 and pPGM-3 including nuclear matrix attachment region of interferon β gene. Those expression vectors confer position independent expression of the introduced foreign gene, thus increasing the frequency of colonies which efficiently express the recombinant protein.
摘要翻译：本发明涉及包括人干扰素β的核基质连接区的哺乳动物表达载体，更具体地涉及包括干扰素β基因的核基质连接区的pPGM-1，pPGM-2和pPGM-3。这些表达载体赋予引入的外源基因的位置无关表达，从而增加有效表达重组蛋白的菌落的频率。

9. 发明申请

US20060013823A1 ANTICANCER AGENT 失效
标题翻译： ANTICANCER代理
公开(公告)号：US20060013823A1
公开(公告)日：2006-01-19
申请号：US11162817
申请日：2005-09-23
申请人： Jang-Seong KIM , Jin-Hyung AHN , Hyun-Kyung YU , Ho-Jeong LEE , Doo-Hong PARK , Yeup YOON
发明人： Jang-Seong KIM , Jin-Hyung AHN , Hyun-Kyung YU , Ho-Jeong LEE , Doo-Hong PARK , Yeup YOON
IPC分类号： A61K39/00 , C07H21/04 , C07K14/82
CPC分类号： A61K38/1709
摘要： The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.
摘要翻译：本申请公开了一种减少肿瘤生长的方法，其包括使肿瘤与具有肿瘤生长的有效量的包含LK8或LK68蛋白或其功能等同的氨基酸变体和其药学上可接受的载体的组合物接触肿瘤。

10. 发明申请

US20120237921A1 FULL GENOME DNA OF HUMAN CYTOMEGALOVIRUS STRAIN JHC ISOLATED FROM KOREAN PATIENT AND OPEN READING FRAMES THEREOF 有权
标题翻译：来自韩国患者的人脑细胞病毒JHC分离的全基因组DNA及其开放阅读框架
公开(公告)号：US20120237921A1
公开(公告)日：2012-09-20
申请号：US13306080
申请日：2011-11-29
申请人： Chan Hee LEE , Yeup YOON
发明人： Chan Hee LEE , Yeup YOON
IPC分类号： C12Q1/70 , C07H21/04 , C07K14/045 , C12N1/21
CPC分类号： C07K14/045 , C12N2710/16121
摘要： Provided are a full genome DNA of a human cytomegalovirus (HCMV) strain JHC isolated from Korean patients and open reading frames (ORFS) thereof and, more particularly, UL1, UL119 and RL6.
摘要翻译：提供了从韩国患者和其开放阅读框（ORFS）分离的人巨细胞病毒（HCMV）菌株JHC，更具体地，UL1，UL119和RL6分离的全基因组DNA。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式